A B S T R A C T The effects of chemotherapy, with nitrosoureas or dimethyl-triazeno-imidazole-carboxamide (DTIC), or immunotherapy with Bacillus Calmette-Guerin (BCG), on cell-mediated immunity (CMI), and serum blocking factor (BF) to melanoma cells were studied in 23 patients. Studies were performed with autologous or allogenic melanoma target cells obtained from recent biopsy, in 16 mm diameter plastic wells. Assays for lymphocyte-mediated cytotoxicity and BF were performed at weekly intervals over the course of3-4 mo, with some studies extending beyond 3 yr. The specificity of cytotoxicity was good with these methods. Nine patients given nitrosoureas, predominantly methyl-chloroethyl-cyclohexylnitrosourea, showed a transient decline in CMI from 42.2 to 14% 3 wk after administration of a single dose of the agent, with a rapid recovery within 1 wk. 10 patients given 5-day courses of DTIC at 3-wk intervals showed no decline in CMI after two courses, and 7 of the 10 had no decline even after three courses. Three of the four patients who achieved a remission lost BF previously present; BF reappeared in both patients studied during a subsequent relapse. BCG intradermally or intralesionally elevated CMI within 2 mo after initiation of therapy, but despite continuation of the injections CMI returned to base line in all but two of the nine patients studied. These results indicate that chemotherapy for melanoma with nitrosoureas
A B S T R A C T The effects of chemotherapy, with nitrosoureas or dimethyl-triazeno-imidazole-carboxamide (DTIC), or immunotherapy with Bacillus Calmette-Guerin (BCG), on cell-mediated immunity (CMI), and serum blocking factor (BF) to melanoma cells were studied in 23 patients. Studies were performed with autologous or allogenic melanoma target cells obtained from recent biopsy, in 16 mm diameter plastic wells. Assays for lymphocyte-mediated cytotoxicity and BF were performed at weekly intervals over the course of3-4 mo, with some studies extending beyond 3 yr. The specificity of cytotoxicity was good with these methods. Nine patients given nitrosoureas, predominantly methyl-chloroethyl-cyclohexylnitrosourea, showed a transient decline in CMI from 42.2 to 14% 3 wk after administration of a single dose of the agent, with a rapid recovery within 1 wk. 10 patients given 5-day courses of DTIC at 3-wk intervals showed no decline in CMI after two courses, and 7 of the 10 had no decline even after three courses. Three of the four patients who achieved a remission lost BF previously present; BF reappeared in both patients studied during a subsequent relapse. BCG intradermally or intralesionally elevated CMI within 2 mo after initiation of therapy, but despite continuation of the injections CMI returned to base line in all but two of the nine patients studied. These results indicate that chemotherapy for melanoma with nitrosoureas or DTIC at these schedules is not pro- INTRODUCTION It has been appreciated since the late 1950's that many of the agents commonly used in the chemotherapy of cancer are immunosuppressive (1) . This has led to an extension of their use, such as in the therapy of allograft rejection and autoimmune disorders. However, during the same period oftime, other investigations have emphasized the importance of the immune response in the rejection of tumors in rodents, and its probable importance in man (2, 3) . Oncologists treating patients with cancer have been justifiably concerned about the possible immunosuppressive effects of chemotherapeutic agents, since suppression of tumor-specific immunity might prevent optimal tumoricidal effects. One approach to analyzing this problem has been to test patients with exogenous antigens during the course of chemotherapy, to judge whether their immunological capacity was impaired. These studies have generally demonstrated immunosuppression by several different agents (4) (5) (6) , although at least one agent, dimethyl-triazeno-imidazolecarboxamide (DTIC),1 was much less suppressive than most (7) . Yet it has remained possible that the response towards tumor-associated antigens (tumorspecific immunity) might be very different from that towards the exogenous microbial and chemical antigens used to test general immunological capacity. We therefore decided to study the influence of chemotherapy upon immunity to antigenic tumor cells, with melanoma in man as a model system.
The immtunological response to human melanoma has been well-studied by several investigators (8) (9) (10) (11) (12) (13) , and some of the earliest attempts to utilize active immunotherapy as a mode of treatment in man were in this disease (14) . Indeed, the regression of intradermal nodules in one-half the patients who received Bacillus Calmette-Guerin (BCG) intralesionally (14) , as well as the spontaneous regressions occasionally observed in the untreated disease, have strongly suggested that melanoma epitomizes those tumors that potentially might be rejected by an immunocompetent host. Lymphocyte-mediated immunity (cell-mediated immunity, [CMI] ) is usually found in patients with melanoma, and is generally higher in patients with local or recently resected disease (10) . Serum blocking factor (BF) present in many patients with disseminated disease decreases or abrogates the effectiveness of cytotoxic lymphocytes in vitro, and significantly reduces the CMI obtainable with even high ratios of lymphocytes to target tumor cells (8) . The presence or absence of BF has been said to correlate with the statuis of the disease (9, 11), but whether BF simply reflects or somehow causes metastasis is an important unresolved issue.
We have studied patients treated with standard schedules of DTIC or one of the nitrosourea derivatives (e.g., methyl-chloroethyl-cyclohexyl-nitrosourea, [ 23 patients were studied. Of these, seven had recently undergone surgical resection of their primary tumor site and usually of regional lymph nodes as treatment for Stage II melanoma. The other 16 patients had metastatic melanoma involving one or more viscera, or the subcutaneous or intradermal regions. Several of the patients were followed from a time at which they had no evidence of disease through the development of metastases and treatment with one or more chemotherapeutic agents.
Immunoprophylactic therapy of patients with Stage II melanoma (involving regional lymph nodes) after surgery consisted of the intradermal inoculation of BCG into uninvolved skin of the deltoid region or back. This route was chosen because the number of organisms inoculated could be precisely quantitated, permitting correlations of dose and response. BCG was inoculated intralesionally into four patients with intradermal melanoma. Chemotherapy consisted of DTIC or one of the nitrosoureas, either cyclohexyl-chloroethyl-nitrosourea (CCNU) or methyl-CCNU. DTIC was given as a 5-day course of 150-250 mg/m2/day (12) , who have specifically addressed themselves to this problem.
Effect of chemotherapy on BF. Three of the four patients (J. McH., J. P., R. P., and S. C.) who achieved a good partial remission after chemotherapy had BF before therapy. During remission BF was lost in each patient. Significantly, this loss of BF was noted in two patients during a remission induced by DTIC, an agent previously shown not to be immunosuppressive towards antibody synthesis (7) . Both patients studied during a subsequent relapse regained BF concomitant with the onset of relapse. BF 4 daily prednisone (20-60 mg) failed to alter CMI -3 mo, then biweekly for 3 more mo or until relapse. (Fig. 4) . re was a transient increase in CMI in four of (b) J. P., a 55-yr-old man, was given BCG intrapatients treated with intradermal BCG within 2 dermally despite a residual 5 mm intradermal nodule of initiation of therapy ( Fig. 3 and Appendix II). at the periphery of the grafted site of primary re-;pite continuation of BCG, CMI returned es-section. His course underscores many of the points tially to pretreatment levels in all but two pa-we have described above, and so is presented graphits. It was possible to increase CMI again by in-cally in Fig. 5 . Within 2 wk after surgical removal of sing the dose of intradermal BCG, but the severity a large subcutaneous tumor mass, BF was undetectable ocal inflammatory reactions made continuation at in the serum. No medical therapy was given during ,e high levels infeasible. All patients but L. R. and this period. BCG intradermally and intralesionally B. H. have relapsed with melanoma.
Intralesional BCG was effective in causing the rejection of dermal nodules in two of three patients (E. H. and M. G.). CMI reached a peak in 5 wk in two of the three, but declined rapidly in both. The third patient had no increase despite a good clinical response.
Of some concern was the appearance of BF in several patients during immunoprophylaxis with BCG. Three patients with no evidence of disease whose serum did not block CMI before therapy developed BF within 12 wk of the initiation of therapy. One of these, A. J., had a significant rise in CMI but was later found to have BF coincident with the clinical complaint of ataxia. Paraspinal metastasis was discovered and resected, but widespread dissemination occurred shortly thereafter. L. R., a 44-yr-old man, developed BF 12 wk after starting BCG, which was stopped after eight injections in July 1972. BF was again present 2 mo later, but was absent 18 and 27 mo later. As of January 1977 there is no evidence of recurrent disease. E. W. developed BF when her nasopharyngeal melanoma recurred and disseminated. Three patients had consistent helper activity of serum, i.e., their serum elevated CMI 20% on three or more obtained with [1251 ]5-iodo-2'-deoxyuridine-labeled melanoma cells and an established line of melanoma cells, making exact comparison with the present results somewhat complicated. Nevertheless, the trend of the results with multiprong vaccination with BCG was the same. It is entirely possible that the dose and strain of BCG were responsible for poor immunostimulation, but this point must await direct comparisons. While the ultimate jtdgment of the utility of BCG will be based on the therapeutic evidence from randomized controlled trials and not from our limited data, we have not yet adduced supportive immunological evidence for its efficacy.
It should be emphasized that we were concerned in these studies almost exclusively with the effects of therapy on immunity to tumor associated antigens and not the clinical response, yet we hoped that the assay chosen might reflect in vivo antitumor immunity. Several investigators (9, 11) have found general correlations between the clinical course of patients with melanoma and levels of CMI and BF, measured in the peripheral blood, although individual patients have shown some discrepancies. A far stronger correlation has been found in animals with various tumors (3). While several of our patients manifested changes in measurable immunity concomitant with a change in clinical status, such as a decrease in CMI or development of BF when metastasis occurred or metastatic disease progressed, several others did not. BF was not invariably found even in patients with disseminated disease with our assay, which differs in several major respects (such as total volume of the incubation mixture and the use of phase-contrast microscopy) from the original microcytoxicity assay. Heppner et al. (11) , with microcytotoxicity, also found BF absent at times in several such patients. In their study as in ours however, only those patients with disseminated disease had BF. It is impossible at this time to assert that immunity of peripheral blood lymphocytes against tumor cells indicates the patient's clinical status or prognosis any better than nonspecific tests of immunocompetence. Yet it seems logical and worthwhile to try to measure immunity to tumor-associated antigens, preferably with a variety of assays for CMI and antibodies, if one is specifically concerned with the patient's immunity to his tumor. Only comparative studies of nonspecific and tumor-specific assays can answer which is more useful. As a start, long-term serial testing of various groups of cancer patients through different stages of their disease and different forms of therapy should help to clarify whether lymphocyte-mediated cytotoxicity or any test of tumor-specific immunity is an accurate reflection of the in vivo circumstances. 18 
